XT
BOLT icon

XTX Topco’s Bolt Biotherapeutics BOLT Stock Holding History

XTX Topco’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-770
Closed -$6.16K – 2396
2025
Q1 		$6.16K Sell
770
-1,475
-66% -$14.2K ﹤0.01% 2293
2024
Q4 		$24K Buy
+2,245
New +$27.1K ﹤0.01% 2013
2024
Q2 		– Sell
-641
Closed -$18K – 1897
2024
Q1 		$18K Sell
641
-317
-33% -$7.34K ﹤0.01% 1622
2023
Q4 		$21.4K Buy
+958
New +$18.6K ﹤0.01% 1353
2023
Q3 		– Sell
-665
Closed -$17K – 1581
2023
Q2 		$17K Buy
+665
New +$21.1K ﹤0.01% 1324
2022
Q1 		– Sell
-623
Closed -$61K – 689
2021
Q4 		$61K Buy
+623
New +$118K 0.03% 539

Other funds holding BOLT

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

XTX Topco's BOLT Position: Q2 2025 in Review

XTX Topco sold out of Bolt Biotherapeutics (BOLT) in Q2 2025, closing a stake of 770 shares — an estimated $6.16K sold.

XTX Topco first reported a position in BOLT in Q4 2021 and held it in 6 quarters. The position peaked at $61K in Q4 2021. 25 funds tracked by Wall St. Rank hold BOLT as of Q2 2025.

  • XTX Topco reported no remaining Bolt Biotherapeutics position as of Q2 2025 after selling out during the quarter.
  • XTX Topco sold 770 Bolt Biotherapeutics shares in Q2 2025, an estimated $6.16K.
  • XTX Topco first reported a position in Bolt Biotherapeutics in Q4 2021 and held it in 6 quarters.
  • XTX Topco's Bolt Biotherapeutics position peaked at $61K in Q4 2021.
  • 25 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q2 2025.

Based on XTX Topco's 13F filing for Q2 2025, filed 12 Aug 2025.